Table 4: Linear regression analysis for associated factors of QTc at baseline.
|
|
Univariate model (n = 274) |
Multivariate model (n = 258) |
||||
|
Predictive value |
B |
p-value |
95 % CI |
B |
p-value |
95 % CI |
|
Constant (intercept) |
|
|
|
412.85 |
< 0.001 |
406.76-418.93 |
|
Sex |
14.12 |
< 0.001 |
6.61-21.63 |
10.86 |
0.006 |
3.08-18.65 |
|
Cardiac family history |
2.60 |
0.599 |
-7.10-12.30 |
-1.93 |
0.693 |
-11.53-7.68 |
|
Cardiac diseases |
-0.85 |
0.809 |
-7.72-6.03 |
1.48 |
0.666 |
-5.27-8.23 |
|
Diabetes Mellitus |
9.32 |
0.243 |
-6.36-24.99 |
|
|
|
|
Treatment duration in years |
7.32 |
< 0.001 |
3.15-11.49 |
|
|
|
|
Methadone dosage T0 |
0.21 |
< 0.001 |
0.12-0.31 |
0.25 |
< 0.001 |
0.15-0.34 |
|
Cocaine use T0 |
0.84 |
0.800 |
-5.64-7.31 |
2.61 |
0.431 |
-3.90-9.12 |
|
Increased GGT (> 110 U/L) T0 |
8.78 |
0.146 |
-3.08-20.64 |
|
|
|
|
Increased AST (> 70 umol/L) T0 |
15.93
|
0.012 |
3.52-28.35 |
|
|
|
|
CYP3A4 inductora |
-3.72 |
0.729 |
-24.80-17.37 |
-12.50 |
0.236 |
-33.25-8.24 |
|
CYP3A4 inhibitora |
-18.33 |
0.224 |
-47.93-11.28 |
-29.03 |
0.049 |
-57.89 - -0.16 |
|
QTc prolongator intermediateb |
25.78 |
0.002 |
9.59-41.96 |
25.82 |
0.005 |
7.92-43.72 |
|
QTc prolongator lowb |
-3.18 |
0.833 |
-32.85-26.50 |
-11.54 |
0.518 |
-46.62-23.54 |
Sample sizes (n = 274 and n = 258) are based on complete cases; CI: Confidence Interval; AST: Aspartate Aminotransferase; GGT = γ-Glutamyltransferase; aCYP3A4 inductor or inhibitor taken by patients. The list of medications 'known' to induce or inhibit CYP3A4 enzymes is listed in Supplemental Digital Content 1; bQTc prolonging medicine taken by patients. The list of medications 'known' to prolongate QTc interval and potential cause Torsades de Pointes are specified into three categories; high, intermediate or low and listed in Supplemental Digital Content 2.